VINCENT MED (01612) Reports Interim Results with Shareholder Profit of HK$51.629 Million, Up 55.1% YoY

Stock News

Aug 20

VINCENT MED (01612) announced its interim results for the six months ended June 30, 2025. The group achieved revenue of HK$449 million, representing an 18.05% year-on-year increase. Profit attributable to owners of the company reached HK$51.629 million, up 55.1% compared to the same period last year. Basic earnings per share stood at HK$0.0803.

The strong performance in the first half of 2025 was primarily driven by a 28.6% increase in revenue from the imaging disposable products segment. The respiratory products segment returned to growth, with gains sufficient to offset the decline in contributions from the orthopedic support and rehabilitation equipment segment.

Supported by expanded economies of scale, improved operational efficiency, and reduced inventory provisions, gross profit increased by 33.4% to HK$159 million. The gross margin improved from 31.3% to 35.4%.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1160979322"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1160979322\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1160979322?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-20 16:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1160979322","market":"nz","top_or_hot":-1,"title":"VINCENT MED (01612) Reports Interim Results with Shareholder Profit of HK$51.629 Million, Up 55.1% YoY","media":"Stock News","content":"<p>VINCENT MED (01612) announced its interim results for the six months ended June 30, 2025. The group achieved revenue of HK$449 million, representing an 18.05% year-on-year increase. Profit attributable to owners of the company reached HK$51.629 million, up 55.1% compared to the same period last year. Basic earnings per share stood at HK$0.0803.</p>\n<p>The strong performance in the first half of 2025 was primarily driven by a 28.6% increase in revenue from the imaging disposable products segment. The respiratory products segment returned to growth, with gains sufficient to offset the decline in contributions from the orthopedic support and rehabilitation equipment segment.</p>\n<p>Supported by expanded economies of scale, improved operational efficiency, and reduced inventory provisions, gross profit increased by 33.4% to HK$159 million. The gross margin improved from 31.3% to 35.4%.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>VINCENT MED (01612) Reports Interim Results with Shareholder Profit of HK$51.629 Million, Up 55.1% YoY</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVINCENT MED (01612) Reports Interim Results with Shareholder Profit of HK$51.629 Million, Up 55.1% YoY\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-08-20 16:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>VINCENT MED (01612) announced its interim results for the six months ended June 30, 2025. The group achieved revenue of HK$449 million, representing an 18.05% year-on-year increase. Profit attributable to owners of the company reached HK$51.629 million, up 55.1% compared to the same period last year. Basic earnings per share stood at HK$0.0803.</p>\n<p>The strong performance in the first half of 2025 was primarily driven by a 28.6% increase in revenue from the imaging disposable products segment. The respiratory products segment returned to growth, with gains sufficient to offset the decline in contributions from the orthopedic support and rehabilitation equipment segment.</p>\n<p>Supported by expanded economies of scale, improved operational efficiency, and reduced inventory provisions, gross profit increased by 33.4% to HK$159 million. The gross margin improved from 31.3% to 35.4%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01612","symbol_name":"永胜医疗","start_time":0,"source_url":"","article_id":"1160979322","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1160979322","pubTimestamp":1755679224,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"VINCENT MED (01612) announced its interim results for the six months ended June 30, 2025. The group achieved revenue of HK$449 million, representing an 18.05% year-on-year increase. Profit...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01612":"永胜医疗","BK1100":"医疗保健设备"},"translate_title":"VINCENT MED(01612)公布中期业绩股东溢利5162.9万港元同比增长55.1%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01612":1},"content_text":"VINCENT MED (01612) announced its interim results for the six months ended June 30, 2025. The group achieved revenue of HK$449 million, representing an 18.05% year-on-year increase. Profit attributable to owners of the company reached HK$51.629 million, up 55.1% compared to the same period last year. Basic earnings per share stood at HK$0.0803.\nThe strong performance in the first half of 2025 was primarily driven by a 28.6% increase in revenue from the imaging disposable products segment. The respiratory products segment returned to growth, with gains sufficient to offset the decline in contributions from the orthopedic support and rehabilitation equipment segment.\nSupported by expanded economies of scale, improved operational efficiency, and reduced inventory provisions, gross profit increased by 33.4% to HK$159 million. The gross margin improved from 31.3% to 35.4%.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}